Dyne Therapeutics (NASDAQ:DYN) Releases Earnings Results, Beats Estimates By $0.02 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings results on Monday. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02, Zacks reports.

Dyne Therapeutics Trading Down 0.5 %

NASDAQ:DYN opened at $43.42 on Wednesday. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $45.46. The stock has a 50-day moving average price of $38.13 and a 200 day moving average price of $30.47. The stock has a market capitalization of $3.79 billion, a P/E ratio of -10.99 and a beta of 1.07.

Analysts Set New Price Targets

A number of brokerages have commented on DYN. Jefferies Financial Group upped their price target on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, May 20th. Morgan Stanley upped their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday. HC Wainwright upped their price target on Dyne Therapeutics from $48.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. upped their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th. Finally, Piper Sandler upped their price target on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.89.

Insider Buying and Selling

In related news, COO Susanna Gatti High sold 29,787 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the completion of the transaction, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at $5,209,207.92. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Oxana Beskrovnaya sold 2,705 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $76,470.35. Following the completion of the transaction, the insider now directly owns 149,647 shares of the company’s stock, valued at $4,230,520.69. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Susanna Gatti High sold 29,787 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87. Following the transaction, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at $5,209,207.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 202,133 shares of company stock worth $6,500,387. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.